Artificial intelligence will drive an unprecedented natural-gas deficit, this investor warns. Here are the stocks to buy before the crunch.
Chronometer Partners’ Matthew Smith says investors and markets are not prepared for a natural-gas shortage.
Chronometer Partners’ Matthew Smith says investors and markets are not prepared for a natural-gas shortage.
Key insight: Russell Vought, who is acting Director of the Consumer Financial Protection Bureau, said he believes the bureau shouldn’t exist in its current form. Forward look: House Democrats can wield a number of tools if they retake the lower chamber in November. The House Financial Services Committee is one of few panels with subpoena…
Key insight: Robinhood is pairing tokenized equities, stablecoin lending and AI-driven trading tools with an international expansion spanning 120+ countries, the U.K., and Canada. Expert quote: “If you have stocks tokenized and stablecoins, you can build financial services using them without any trust in the service provider. You don’t have to trust Robinhood, you can…
Earlier in 2026, the BoC flagged a two-sided risk profile: the possibility of rate cuts if growth disappointed more sharply than forecast, and potential hikes if energy prices from the Iran conflict drove a sustained, generalized consumer price shock. In recent weeks, neither scenario has materialized. Inflation concerns retreat Higher oil prices stemming from restricted…
Philadelphia Eagles running back Saquon Barkley‘s $4 million Pennsylvania home was the subject of a home invasion over the weekend—while the athlete was at the property with his family. Local officials confirmed that the Chester County, PA, property was targeted in an incident that took place on July 18 at around 5 a.m., while revealing…
Senator Ron Wyden, ranking Democrat on the Senate Finance Committee, said the plan would benefit the Trump family and “make Wall Street traders rich,” while Senator Elizabeth Warren called it “an egregious scheme to profit off the presidency and enrich Wall Street,” both according to Reuters. Ethics specialists agreed on the optics while splitting on the law. …
One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids Prevention of vision-threatening events…